Yale Cancer Center Study Suggests Improved Diagnostic Testing Needed to Guide HER2 Breast Cancer Treatment
Yale Cancer Center/Smilow Cancer HospitalA new study by researchers at Yale Cancer Center shows using current standard human epidermal growth factor receptor 2 (HER2) assays as a diagnostic test may result in a mis-assignment of patients for treatment for breast cancer with a promising new drug.